Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Publications indexed to the term Leukemia, Myelogenous, Chronic, BCR-ABL Positive

FacultyTitle
1Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. (Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, Laine D, Sabo J, Gu E, Cortes JE) Future Oncol 2024;20(38):3065-3075       10 Citations
1BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis. (Kockerols C, Valk PJM, Dulucq S, Nicolini FE, Mahon FX, Atallah E, Mauro MJ, Radich JP, Bernardi S, Russo D, Farina M, Mori S, Gambacorti-Passerini C, Civettini I, Lu L, Yeung D, Branford S, Colafigli G, Breccia M, Hogenbirk P, van Rosmalen J, Cornelissen JJ, Westerweel PE) Am J Hematol 2024 Aug;99(8):1632-1635       8 Citations
1Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. (Winn AN, Atallah E, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE) JAMA Netw Open 2023 Dec 01;6(12):e2347950       6 Citations
4Interleukin-9 production by type 2 innate lymphoid cells induces Paneth cell metaplasia and small intestinal remodeling. (Yuan C, Rayasam A, Moe A, Hayward M, Wells C, Szabo A, Mackenzie A, Salzman N, Drobyski WR) Nat Commun 2023 Dec 02;14(1):7963       15 Citations
1A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I. (Chimge NO, Chen MH, Nguyen C, Zhao Y, Wu X, Gonzalez PG, Ogana H, Hurwitz S, Teo JL, Chen X, Du J, Jin V, Kim YM, Ono M, Argüello RJ, Kahn M) Curr Mol Pharmacol 2024;17:e060923220758       1 Citation
1SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML). (Mikhaeel S, Atallah E) Clin Lymphoma Myeloma Leuk 2023 May;23(5):333-339       4 Citations
1Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. (Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D) J Cancer Res Clin Oncol 2023 Aug;149(9):6247-6262       19 Citations
1CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI). (Sasaki K, Mauro MJ, Levy MY, Atallah EL, Koller P, Maegawa R, Damon A, Kumar J, Khan M, Cortes JE) Clin Lymphoma Myeloma Leuk 2022 Oct;22 Suppl 2:S299    
1Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. (Pettit K, Rezazadeh A, Atallah EL, Radich J) Am Soc Clin Oncol Educ Book 2022 Apr;42:1-19    
2Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. (Flynn KE, Atallah E, Lin L, Shah NP, Silver RT, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP) Haematologica 2022 Nov 01;107(11):2641-2649       9 Citations
1Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival. (Guru SA, Sumi MP, Mir R, Beg MMA, Koner BC, Saxena A) BMC Cancer 2022 Apr 14;22(1):405       8 Citations
1Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions. (Schoenbeck KL, Flynn KE) Curr Hematol Malig Rep 2021 Dec;16(6):491-499       20 Citations
1Treatment-Free Remission: the New Goal in CML Therapy. (Atallah E, Sweet K) Curr Hematol Malig Rep 2021 Oct;16(5):433-439       32 Citations
1Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients. (Ali Beg MM, Guru SA, Abdullah SM, Ahmad I, Rizvi A, Akhter J, Goyal Y, Verma AK) Oncol Res Treat 2021;44(10):530-537       7 Citations
1CML derived exosomes promote tumor favorable functional performance in T cells. (Jafarzadeh N, Gholampour MA, Alivand MR, Kavousi S, Arzi L, Rad F, Sadeghizadeh M, Pornour M) BMC Cancer 2021 Sep 07;21(1):1002       23 Citations
2Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. (Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE) J Natl Cancer Inst 2022 Jan 11;114(1):160-164       19 Citations
1Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. (Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V) Leuk Lymphoma 2021 Jul;62(7):1730-1739       4 Citations
3Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. (Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE) JAMA Oncol 2021 Jan 01;7(1):42-50       87 Citations
1Evaluation of Imatinib Concentrations in Samples Submitted for BCR-ABL1 or Imatinib Testing-Evidence to Support Therapeutic Drug Monitoring for Dose Optimization? (Smy L, Sadler AJ, McMillin GA) Ther Drug Monit 2020 Aug;42(4):559-564       9 Citations
2Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. (Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W) Leuk Lymphoma 2020 Dec;61(12):2811-2820       11 Citations
2BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature. (Durand MJ, Hader SN, Derayunan A, Zinkevich N, McIntosh JJ, Beyer AM) Microcirculation 2020 Oct;27(7):e12625       8 Citations
1The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. (Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W) Biol Blood Marrow Transplant 2020 Jun;26(6):1137-1143       19 Citations
3In Reply. (Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E) Oncologist 2020 Apr;25(4):e744-e745    
2Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. (DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W) Biol Blood Marrow Transplant 2020 Mar;26(3):472-479       34 Citations
1Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling. (Himburg HA, Roos M, Fang T, Zhang Y, Termini CM, Schlussel L, Kim M, Pang A, Kan J, Zhao L, Suh H, Sasine JP, Sapparapu G, Bowers PM, Schiller G, Chute JP) J Clin Invest 2020 Jan 02;130(1):315-328       12 Citations
1microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients. (Mirza MAB, Guru SA, Abdullah SM, Rizvi A, Saxena A) Asian Pac J Cancer Prev 2019 Aug 01;20(8):2379-2383       11 Citations
1Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. (Athale U, Hijiya N, Patterson BC, Bergsagel J, Andolina JR, Bittencourt H, Schultz KR, Burke MJ, Redell MS, Kolb EA, Johnston DL) Pediatr Blood Cancer 2019 Sep;66(9):e27827       75 Citations
1Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. (Kota V, Atallah E) Clin Lymphoma Myeloma Leuk 2019 Aug;19(8):480-487       15 Citations
2Patients' perspectives on the definition of cure in chronic myeloid leukemia. (Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E) Leuk Res 2019 May;80:40-42       4 Citations
3Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. (Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E) Oncologist 2019 Sep;24(9):1253-1258       15 Citations
2Treatment-Free Remission in CML: the US Perspective. (Guru Murthy GS, Atallah E) Curr Hematol Malig Rep 2019 Feb;14(1):56-61       12 Citations
3Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. (Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W) Blood Adv 2018 Nov 13;2(21):2922-2936       38 Citations
1Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. (Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME) Biol Blood Marrow Transplant 2019 Feb;25(2):321-327       9 Citations
1Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. (Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C, GV12-02 Writing Committee on behalf of the CIBMTR® Graft-versus-Host Disease Working Committee) Haematologica 2018 Oct;103(10):1708-1719       12 Citations
4Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. (Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE) BMC Cancer 2018 Apr 02;18(1):359       17 Citations
1hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival. (Pellicano F, Park L, Hopcroft LEM, Shah MM, Jackson L, Scott MT, Clarke CJ, Sinclair A, Abraham SA, Hair A, Helgason GV, Aspinall-O'Dea M, Bhatia R, Leone G, Kranc KR, Whetton AD, Holyoake TL) Blood 2018 Apr 05;131(14):1532-1544       40 Citations
1Dasatinib dose management for the treatment of chronic myeloid leukemia. (Talpaz M, Saglio G, Atallah E, Rousselot P) Cancer 2018 Apr 15;124(8):1660-1672       22 Citations
1PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India. (Guru SA, Mir R, Bhat M, Najar I, Zuberi M, Sumi M, Masroor M, Gupta N, Saxena A) Tumour Biol 2017 Oct;39(10):1010428317713857       3 Citations
3Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. (Narra RK, Flynn KE, Atallah E) Curr Hematol Malig Rep 2017 Oct;12(5):415-423       10 Citations
1Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. (Khoury HJ, Williams LA, Atallah E, Hehlmann R) Am Soc Clin Oncol Educ Book 2017;37:468-479       12 Citations
1Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. (Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW) Blood 2017 Jan 12;129(2):162-170       75 Citations
3Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. (Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W) Biol Blood Marrow Transplant 2016 Jun;22(6):1056-1064       30 Citations
1Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia. (Abedin S, Platanias LC) Leuk Lymphoma 2016 Jul;57(7):1503-4       1 Citation
2Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. (Flynn KE, Atallah E) Curr Hematol Malig Rep 2016 Apr;11(2):80-5       47 Citations
1Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy. (Broglie L, Hijiya N, Helenowski IB, Dilley K, Schneiderman J, Tse W, Duerst R, Kletzel M, Morgan E, Chaudhury S) Leuk Lymphoma 2016;57(4):949-52       5 Citations
1Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. (Kwon HY, Bajaj J, Ito T, Blevins A, Konuma T, Weeks J, Lytle NK, Koechlein CS, Rizzieri D, Chuah C, Oehler VG, Sasik R, Hardiman G, Reya T) Cell Stem Cell 2015 Aug 06;17(2):152-164       66 Citations
4Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. (Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2015 Mar;21(3):552-8       12 Citations
5Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ, Graft-vs-Host Disease Working Committee of the CIBMTR) Biol Blood Marrow Transplant 2015 Feb;21(2):266-74       397 Citations
2Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. (Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE) Biol Blood Marrow Transplant 2015 Jan;21(1):55-9       31 Citations
4Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. (Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, Shaw B, Storek J, Wood WA, Woolfrey AE, Anasetti C) Blood 2014 Oct 16;124(16):2596-606       257 Citations
1Strange bedfellows: mitotically active chronic myeloid leukemia in molecular complete remission, detected in focal lesion of myeloma. (Guru Murthy GS, Sawyer J, Alapat D, Samant R, Barlogie B) Clin Lymphoma Myeloma Leuk 2014 Aug;14(4):e127-9       2 Citations
1Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia. (Anzalone CL, Cohen PR, Kurzrock R, Cortes JE) Dermatol Online J 2014 Jan 15;20(1):21242       6 Citations
1It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. (Westin JR, Kurzrock R) Mol Cancer Ther 2012 Dec;11(12):2549-55       52 Citations
1Chronic myelogenous leukemia for primary care physicians. (Torgerson SR, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):168-76       10 Citations
1Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. (Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D) Blood 2012 Apr 26;119(17):4083-90       49 Citations
2Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. (Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ) Bone Marrow Transplant 2012 Jun;47(6):810-6       83 Citations
1Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. (Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL) Br J Haematol 2011 Apr;153(2):244-52       19 Citations
3Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. (Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, Bolwell B, Wingard JR, Socie G) Blood 2011 Jan 06;117(1):316-22       187 Citations
1Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. (Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA) J Clin Oncol 2010 Nov 01;28(31):e629-32       31 Citations
1Bone marrow or peripheral blood. (Eapen M) Biol Blood Marrow Transplant 2010 Jun;16(6):868-9    
1Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. (Bilgi N, Bell K, Ananthakrishnan AN, Atallah E) Ann Pharmacother 2010 May;44(5):926-8       110 Citations
2Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. (Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M, Horowitz MM, Rizzo JD) J Clin Oncol 2010 Apr 10;28(11):1888-95       114 Citations
1Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet) J Clin Oncol 2009 Dec 10;27(35):6041-51       1163 Citations
1Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. (Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn JY, Cervantes F, Copelan E, Gale R, Gratwohl A, Khoury HJ, McCarthy P, Marks DI, Szer J, Woolfrey A, Cortes-Franco J, Horowitz MM, Arora M, Chronic Leukemia Working Committee) Biol Blood Marrow Transplant 2009 Nov;15(11):1475-8       38 Citations
2The effect of smoking on allogeneic transplant outcomes. (Marks DI, Ballen K, Logan BR, Wang Z, Sobocinski KA, Bacigalupo A, Burns LJ, Gupta V, Ho V, McCarthy PL, Ringdén O, Schouten HC, Seftel M, Rizzo JD) Biol Blood Marrow Transplant 2009 Oct;15(10):1277-87       29 Citations
1Resolution of rheumatoid arthritis symptoms with imatinib mesylate. (Vernon MR, Pearson L, Atallah E) J Clin Rheumatol 2009 Aug;15(5):267       10 Citations
1Practical considerations for the management of patients in the tyrosine kinase inhibitor era. (O'Dwyer M, Atallah E) Semin Hematol 2009 Apr;46(2 Suppl 3):S16-21       12 Citations
1The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. (Burke MJ, Willert J, Desai S, Kadota R) Pediatr Blood Cancer 2009 Dec;53(6):992-5       10 Citations
1Molecular imaging of Bcr-Abl phosphokinase in a xenograft model. (Wu JY, Yang DJ, Angelo LS, Kohanim S, Kurzrock R) Mol Cancer Ther 2009 Mar;8(3):703-10       5 Citations
1HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. (Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C, Nademanee A, McGlave P, Horowitz MM, Petersdorf EW) J Clin Oncol 2009 Apr 01;27(10):1644-52       96 Citations
1Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74       12 Citations
1Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. (Hahn T, McCarthy PL Jr, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringdén O) J Clin Oncol 2008 Dec 10;26(35):5728-34       173 Citations
2Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. (Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT) Blood 2008 Oct 15;112(8):3500-7       120 Citations
3Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. (Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz MM, Collins R Jr) Bone Marrow Transplant 2008 Aug;42(3):201-5       43 Citations
1Individual physician practice variation in hematopoietic cell transplantation. (Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M, Kernan NA, Loberiza FR Jr, Soiffer RJ, Eapen M) J Clin Oncol 2008 May 01;26(13):2162-70       46 Citations
3Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma. (Ahmed MS, Kroft SH, Davis NB, King DM, Cheng YC) Leuk Res 2008 Sep;32(9):1476-9       6 Citations
1Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. (Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W) Leuk Lymphoma 2008 Mar;49(3):531-7       8 Citations
1Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. (Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D) Blood 2008 Jan 15;111(2):816-28       40 Citations
1Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. (Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM, Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research) Br J Haematol 2007 Jun;137(5):461-7       71 Citations
1Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. (Mehta PA, Eapen M, Klein JP, Gandham S, Elliott J, Zamzow T, Combs M, Aplenc R, MacMillan ML, Weisdorf DJ, Petersdorf E, Davies SM) Br J Haematol 2007 Apr;137(2):152-7       16 Citations
2Limitations of Sokal score in patients with chronic myeloid leukemia. (Hamadani SM, Chaudhary L) J Coll Physicians Surg Pak 2007 Mar;17(3):182; author reply 182    
1Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. (Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB) J Dermatolog Treat 2007;18(1):13-8       19 Citations
1Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. (Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ) Blood 2007 Jun 01;109(11):5058-61       258 Citations
1Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. (Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC) Bone Marrow Transplant 2007 Feb;39(4):249-51       20 Citations
1Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. (Atallah E, Cortes J) Curr Opin Hematol 2007 Mar;14(2):138-44       3 Citations
1In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. (Atallah E, Kantarjian H, Cortes J) Nat Med 2007 Jan;13(1):14; author reply 15-6       39 Citations
1Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance. (Kurzrock R, Talpaz M, Li L, Estrov Z) Leuk Lymphoma 2006 Aug;47(8):1651-64       2 Citations
1Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet) Blood 2006 Sep 15;108(6):1809-20       1146 Citations
1Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. (Khoury HJ, Loberiza FR Jr, Ringdén O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, Martino R, McCarthy PL, Tiberghien P, Verdonck LF, Horowitz MM) Blood 2006 Feb 15;107(4):1712-6       78 Citations
2Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. (Baker KS, Loberiza FR Jr, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander AR, Horowitz MM, Keating A, Weisdorf DJ) J Clin Oncol 2005 Oct 01;23(28):7032-42       54 Citations
1Immune therapy of chronic myelogenous leukemia. (Gale RP, Horowitz MM, Talpaz M, Scheinberg DA, Molldrem J, Li Z, Baccarani M, Goldman JM, Tura S) Leuk Res 2005 May;29(5):583-6       1 Citation
1Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. (Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B) Blood 2005 Jun 15;105(12):4878-84       431 Citations
1In-vivo generation of leukaemia-derived dendritic cells. (Kolb HJ, Rank A, Chen X, Woiciechowsky A, Roskrow M, Schmid C, Tischer J, Ledderose G) Best Pract Res Clin Haematol 2004 Sep;17(3):439-51       18 Citations
4Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. (Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringdén O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M) Bone Marrow Transplant 2004 Oct;34(8):721-7       209 Citations
1The second international congress on myeloproliferative and myelodysplastic syndromes. (Silver RT, Bennett JM, Deininger M, Feldman E, Rafii S, Silverstein RL, Solberg LA, Spivak JL) Leuk Res 2004 Sep;28(9):979-85       6 Citations
1Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. (Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA, Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry) Br J Haematol 2004 Jun;125(5):613-20       83 Citations
1Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. (Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M) Ann Intern Med 2003 May 20;138(10):819-30       285 Citations
1Access to stem cell transplantation: do women fare as well as men? (Mehta P, Pollock BH, Nugent M, Horowitz M, Wingard JR) Am J Hematol 2003 Feb;72(2):99-102       17 Citations
1Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. (Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H) Blood 2003 Mar 01;101(5):1692-7       215 Citations
1Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. (Kantarjian HM, Cortes JE, Rowe JM, Kurzrock R) Semin Hematol 2002 Jul;39(3 Suppl 2):36-8       5 Citations
1Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. (Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H) Cancer 2002 Jun 01;94(11):2996-9       19 Citations
1Chronic myelogenous leukemia in chronic phase. (Kurzrock R, Kantarjian H, Talpaz M) Curr Treat Options Oncol 2001 Jun;2(3):245-52       7 Citations
1The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. (Lee SJ, Klein JP, Anasetti C, Antin JH, Loberiza FR, Bolwell BJ, LeMaistre CF, Litzow MR, Marks D, Waller EK, Matlack M, Giralt S, Horowitz MM) Blood 2001 Dec 01;98(12):3205-11       25 Citations
1Confidence bands for the difference of two survival curves under proportional hazards model. (Zhang MJ, Klein JP) Lifetime Data Anal 2001 Sep;7(3):243-54       26 Citations
1In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation. (Epperson DE, Margolis DA, McOlash L, Janczak T, Barrett AJ) Br J Haematol 2001 Jul;114(1):57-62       19 Citations
1Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. (Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH) Cancer 2001 Jul 15;92(2):406-13       260 Citations
1BCR rearrangement-negative chronic myelogenous leukemia revisited. (Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, Pilat S, Talpaz M) J Clin Oncol 2001 Jun 01;19(11):2915-26       97 Citations
1The BCR gene and philadelphia chromosome-positive leukemogenesis. (Laurent E, Talpaz M, Kantarjian H, Kurzrock R) Cancer Res 2001 Mar 15;61(6):2343-55       124 Citations
1Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. (Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M) Br J Haematol 2000 Dec;111(3):817-25       55 Citations
1Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. (Chen X, Regn S, Raffegerst S, Kolb HJ, Roskrow M) Br J Haematol 2000 Nov;111(2):596-607       59 Citations
1Autoantibodies to Abl and Bcr proteins. (Talpaz M, Qiu X, Cheng K, Cortes JE, Kantarjian H, Kurzrock R) Leukemia 2000 Sep;14(9):1661-6       3 Citations
1Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. (Barrett AJ, Ringdén O, Zhang MJ, Bashey A, Cahn JY, Cairo MS, Gale RP, Gratwohl A, Locatelli F, Martino R, Schultz KR, Tiberghien P) Blood 2000 Jun 01;95(11):3323-7       75 Citations
2Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. (Porter DL, Collins RH Jr, Hardy C, Kernan NA, Drobyski WR, Giralt S, Flowers ME, Casper J, Leahey A, Parker P, Mick R, Bate-Boyle B, King R, Antin JH) Blood 2000 Feb 15;95(4):1214-21       164 Citations
1Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. (Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH, Klein JP, McGlave PB, Schiller G, Gale RP, Rowlings PA, Horowitz MM) Blood 2000 Jan 15;95(2):410-5       29 Citations
1Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. (Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR) Leuk Res 1999 Sep;23(9):817-26       8 Citations
1Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. (Porter DL, Collins RH Jr, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH) Biol Blood Marrow Transplant 1999;5(4):253-61       100 Citations
1The biology of chronic myeloid leukemia. (Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM) N Engl J Med 1999 Jul 15;341(3):164-72       1166 Citations
3T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. (Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 1999 Jul 15;94(2):434-41       78 Citations
1Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. (Kantarjian HM, Talpaz M, O'Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ) Clin Cancer Res 1997 Dec;3(12 Pt 2):2723-33       16 Citations
2The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. (Drobyski WR, Hessner MJ) Leuk Lymphoma 1998 Oct;31(3-4):317-23       3 Citations
1Initial therapy for chronic myelogenous leukemia: playing the odds. (Lee SJ, Anasetti C, Horowitz MM, Antin JH) J Clin Oncol 1998 Sep;16(9):2897-903       29 Citations
2Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. (Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, Keever-Taylor CA) Biol Blood Marrow Transplant 1998;4(1):3-12       7 Citations
1GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. (Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M) Leukemia 1998 Jun;12(6):860-4       51 Citations
1Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. (Kurzrock R, Estrov Z, Kantarjian H, Talpaz M) J Clin Oncol 1998 Apr;16(4):1526-31       53 Citations
1Related donor bone marrow transplantation for chronic myelogenous leukemia. (Passweg JR, Rowlings PA, Horowitz MM) Hematol Oncol Clin North Am 1998 Feb;12(1):81-92       8 Citations
2Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. (Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM) Blood 1998 Mar 01;91(5):1810-9       100 Citations
1Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. (Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH) Ann Intern Med 1997 Dec 15;127(12):1080-8       64 Citations
2Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. (Zhang MJ, Baccarani M, Gale RP, McGlave PB, Atkinson K, Champlin RE, Dicke KA, Giralt S, Gluckman E, Goldman JM, Klein JP, Herzig RH, Masaoka T, O'Reilly RJ, Rozman C, Rowlings PA, Sobocinski KA, Speck B, Zwaan FE, Horowitz MM) Br J Haematol 1997 Oct;99(1):23-9       6 Citations
2Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. (Drobyski WR, Endean DJ, Klein JP, Hessner MJ) Br J Haematol 1997 Aug;98(2):458-66       23 Citations
1The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemia. (Talpaz M, Kantarjian HM, O'Brien S, Kurzrock R) Baillieres Clin Haematol 1997 Jun;10(2):291-305       13 Citations
3Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. (Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb HJ, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang MJ, Horowitz MM) J Clin Oncol 1997 May;15(5):1767-77       433 Citations
1Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. (Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M) Leuk Lymphoma 1997 Mar;25(1-2):121-33       19 Citations
2The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. (Johnson BD, Hanke CA, Truitt RL) Leuk Lymphoma 1996 Sep;23(1-2):1-9       13 Citations
1Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. (Horowitz MM, Rowlings PA, Passweg JR) Bone Marrow Transplant 1996 May;17 Suppl 3:S5-6       110 Citations
4Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. (Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR) Blood 1995 Nov 15;86(10):3987-96       59 Citations
1Interferon-alpha therapy for chronic myelogenous leukemia. (Wetzler M, Kantarjian H, Kurzrock R, Talpaz M) Am J Med 1995 Oct;99(4):402-11       55 Citations
1Cytokines and their antagonists in myeloid disorders. (Estrov Z, Kurzrock R, Talpaz M) Semin Hematol 1995 Jul;32(3):220-31       14 Citations
1Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. (Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink MP, Talpaz M) Blood 1994 Nov 01;84(9):3142-7       61 Citations
1Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. (Silberman G, Crosse MG, Peterson EA, Weston RC, Horowitz MM, Appelbaum FR, Cheson BD) N Engl J Med 1994 Oct 20;331(16):1063-7       54 Citations
1Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. (Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R) J Clin Invest 1994 Oct;94(4):1383-9       99 Citations
1Identical-twin bone marrow transplants for leukemia. (Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringdén O, Stone JA, Bortin MM) Ann Intern Med 1994 Apr 15;120(8):646-52       264 Citations
4Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. (Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F) Blood 1994 Apr 01;83(7):1980-7       126 Citations
1Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha. (Wetzler M, Estrov Z, Talpaz M, Kim KJ, Alphonso M, Srinivasan R, Kurzrock R) Cancer Res 1994 Apr 01;54(7):1837-42       39 Citations
2Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. (Hessner MJ, Roth MS, Drobyski WR, Baxter-Lowe LA) Genet Anal Tech Appl 1994;11(4):90-4       11 Citations
1Bone marrow transplantation in leukemia. (Rowlings PA, Gale RP, Horowitz MM, Bortin MM) J Hematother 1994;3(3):235-8       5 Citations
2Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. (Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM) Blood 1993 Oct 15;82(8):2310-8       343 Citations
1Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. (Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A) Blood 1993 Oct 01;82(7):2235-8       192 Citations
1Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. (Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H) Cancer Res 1993 Aug 01;53(15):3603-10       61 Citations
1Role of interleukin-1 inhibitory molecules in therapy of acute and chronic myelogenous leukemia. (Estrov Z, Kurzrock R, Talpaz M) Leuk Lymphoma 1993 Aug;10(6):407-18       18 Citations
1Chronic myelogenous leukemia: a concise update. (Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M) Blood 1993 Aug 01;82(3):691-703       464 Citations
1Outcome after allogeneic bone marrow transplant for leukemia in older adults. (Ringdén O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA, Speck B, Veum-Stone JA, de Witte T, Bortin MM) JAMA 1993 Jul 07;270(1):57-60       131 Citations
1Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? (Ringdén O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg HJ, Dicke K, Masaoka T, Powles RL) Blood 1993 Feb 15;81(4):1094-101       170 Citations
1Suppression of chronic myelogenous leukemia colony growth by interleukin-4. (Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M) Leukemia 1993 Feb;7(2):214-20       18 Citations
1Philadelphia chromosome-positive chronic myeloid leukemia and thoracic ganglioneuroma. Previously undescribed association. (Shea MP, Abshire TC) Am J Pediatr Hematol Oncol 1993 Feb;15(1):111-4       3 Citations
1Results of bone marrow transplants from human leukocyte antigen-identical sibling donors for treatment of childhood leukemias. A report from the International Bone Marrow Transplant Registry. (Horowitz MM, Bortin MM) Am J Pediatr Hematol Oncol 1993 Feb;15(1):56-64       19 Citations
1Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. (Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M) Exp Hematol 1993 Jan;21(1):80-5       32 Citations
1Predicting results of alternative donor transplants for thalassemia using a chronic myelogenous leukemia model. (Gale RP, Horowitz MM) Bone Marrow Transplant 1993;12 Suppl 1:82-3       1 Citation
1CML: mechanisms of disease initiation and progression. (Wetzler M, Talpaz M, Estrov Z, Kurzrock R) Leuk Lymphoma 1993;11 Suppl 1:47-50       27 Citations
1Merocyanine 540-sensitized photoinactivation of leukemia cells: effects of dose fractionation. (Qiu K, Sieber F) Photochem Photobiol 1992 Oct;56(4):489-93       12 Citations
1Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. (Drobyski WR, Roth MS, Thibodeau SN, Gottschall JL) Bone Marrow Transplant 1992 Sep;10(3):301-4       44 Citations
1Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. (Bortin MM, Horowitz MM, Gale RP, Barrett AJ, Champlin RE, Dicke KA, Gluckman E, Kolb HJ, Marmont AM, Mrsic M) JAMA 1992 Aug 05;268(5):607-12       75 Citations
1Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction. (Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M) Leukemia 1992 Aug;6(8):754-60       43 Citations
1Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. (Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, Kurzrock R) Cancer Res 1992 Mar 01;52(5):1087-90       24 Citations
1Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. (Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU) Cancer 1992 Jan 15;69(2):410-2       27 Citations
1Current status of allogeneic bone marrow transplantation. (Sobocinski KA, Horowitz MM, Rimm AA, Bortin MM) Biomed Pharmacother 1992;46(2-3):57-69       7 Citations
2Report from the International Bone Marrow Transplant Registry. (Rowlings PA, Horowitz MM, Rimm AA, Sobocinski KA, Zhang MJ, Bortin MM) Clin Transpl 1992:83-90       2 Citations
1Transplants in ALL. (Barrett AJ, Horowitz MM) Bone Marrow Transplant 1992;10 Suppl 1:30-6       3 Citations
1A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia. (Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU) Cancer 1991 Nov 15;68(10):2125-30       24 Citations
1Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. (Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R) Blood 1991 Nov 01;78(9):2411-8       137 Citations
1Alteration in bone marrow adherent layer growth factor expression: a novel mechanism of chronic myelogenous leukemia progression. (Wetzler M, Kurzrock R, Lowe DG, Kantarjian H, Gutterman JU, Talpaz M) Blood 1991 Nov 01;78(9):2400-6       68 Citations
1Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. (Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M) Cancer 1991 Oct 01;68(7):1536-7       117 Citations
1Interferon alpha in the therapy of CML. (Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU) Br J Haematol 1991 Oct;79 Suppl 1:38-41       14 Citations
1The molecular pathology of chronic myelogenous leukaemia. (Kurzrock R, Talpaz M) Br J Haematol 1991 Oct;79 Suppl 1:34-7       15 Citations
1Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. (Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M) Blood 1991 Sep 15;78(6):1476-84       97 Citations
1Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. (Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC) Transplantation 1991 Jun;51(6):1190-6       29 Citations
1Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-alpha, and TGF-beta. (Wetzler M, Talpaz M, Lowe DG, Baiocchi G, Gutterman JU, Kurzrock R) Exp Hematol 1991 Jun;19(5):347-51       87 Citations
1Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. (Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU) Ann Intern Med 1991 Apr 01;114(7):532-8       431 Citations
1Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression. (Dhingra K, Talpaz M, Kantarjian H, Ku S, Rothberg J, Gutterman JU, Kurzrock R) Leukemia 1991 Mar;5(3):191-5       48 Citations
1Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia. (Estrov Z, Talpaz M, Chou TC, Kurzrock R, Blake M, Gutterman JU) Leukemia 1991 Feb;5(2):101-7       8 Citations
1Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias. (Dhingra K, Talpaz M, Riggs MG, Eastman PS, Zipf T, Ku S, Kurzrock R) Blood 1991 Jan 15;77(2):238-42       21 Citations
1Constitutive and induced expression of growth factors in normal and chronic phase chronic myelogenous leukemia Ph1 bone marrow stroma. (Wetzler M, Kurzrock R, Taylor K, Spitzer G, Kantarjian H, Baiocchi G, Ku S, Gutterman JU, Talpaz M) Cancer Res 1990 Sep 15;50(18):5801-5       27 Citations
1Update on therapeutic options for chronic myelogenous leukemia. (Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU) Semin Hematol 1990 Jul;27(3 Suppl 4):31-6       26 Citations
1Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. (Gale RP, Horowitz MM) Bone Marrow Transplant 1990 Jul;6 Suppl 1:94-7       28 Citations
1Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. (Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz M) Acta Haematol 1990;83(3):149-51       5 Citations
2Third-party-mediated graft rejection and graft-versus-host disease after T-cell-depleted bone marrow transplantation, as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. (Drobyski W, Thibodeau S, Truitt RL, Baxter-Lowe LA, Gorski J, Jenkins R, Gottschall J, Ash RC) Blood 1989 Nov 01;74(6):2285-94       77 Citations
1Chronic myelogenous leukemia and Sweet syndrome. (Cohen PR, Kurzrock R) Am J Hematol 1989 Oct;32(2):134-7       40 Citations
1Biological molecules in the treatment of hematological disorders. (Kurzrock R, Talpaz M, Gutterman U) Sangre (Barc) 1989 Feb;34(1):53-8    
1Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. (Ringdén O, Horowitz MM) Transplant Proc 1989 Feb;21(1 Pt 3):2989-92       70 Citations
1Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemia. (Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU) Bone Marrow Transplant 1989 Jan;4 Suppl 1:63       4 Citations
1Therapy of chronic myelogenous leukaemia with interferons. (Talpaz M, Kurzrock R, Kantarjian H, Gutterman J) Cancer Surv 1989;8(4):793-8       5 Citations
1Current status of bone marrow transplantation. (Bortin MM, Horowitz MM) Clin Transpl 1989:93-104       7 Citations
1Therapy of chronic myelogenous leukemia with interferon. (Kurzrock R, Gutterman JU, Kantarjian H, Talpaz M) Cancer Invest 1989;7(1):83-91       6 Citations
1Erythromelalgia and myeloproliferative disorders. (Kurzrock R, Cohen PR) Arch Intern Med 1989 Jan;149(1):105-9       80 Citations
1Current status of bone marrow transplantation in humans: report from the International Bone Marrow Transplant Registry. (Bortin MM, Horowitz MM, Gale RP) Nat Immun Cell Growth Regul 1988;7(5-6):334-50       24 Citations